MJA Unveils 2026 Strategic Enhancements and Bolsters Clinical Guideline Focus

The Medical Journal of Australia (MJA) is implementing significant strategic changes for 2026, aiming to substantially enhance its editorial processes and publication model. Concurrently, the journal is reinforcing its commitment to the publication of high-quality clinical guidelines, actively addressing best practices and challenges in their development and dissemination. These efforts are designed to better inform Australian health policy and medical practice.

The MJA's primary objective remains the publication of high-quality research and commentary relevant to Australian health policy and medical practice.

Operational and Publication Model Enhancements for 2026

The MJA has observed a notable increase in submissions, rising from 1,413 in 2023 to 1,619 in 2025. Australian submissions saw growth from 1,020 to 1,087, while international submissions increased from 393 to 532. International submissions now constitute approximately 33% of the total. To maintain the journal's high quality standards, the MJA is intensifying its focus on papers that align precisely with its defined scope.

Submissions are now systematically categorized to streamline the editorial process:

• Irrelevant Content: Papers lacking relevance to Australian healthcare or exhibiting characteristics of "paper mills."
• Low Priority Relevant Content: Content relevant to Australian healthcare but not meeting high priority qualitative criteria (e.g., high burden of disease, public health interest, Aboriginal and Torres Strait Islander-led research, immediate clinical/policy impact).
• Content with Fundamental Issues: Papers meeting qualitative criteria but containing significant design or writing flaws.
• Publishable Content: Submissions meeting criteria, well-reported, and without obvious issues, deemed suitable for peer review.

Key Operational Adjustments for 2026

To accommodate the growing volume and maintain quality, several key operational adjustments are being introduced:

Effective 2026, the in-house manuscript decision-making team will expand. It will include an Editor-in-Chief, Deputy Editor, two Senior Editors, and five part-time Associate Editors. This strategic expansion aims to broaden the journal's reach and build essential editorial capacity.

The MJA plans to be more selective in sending papers for external peer review. This change aims to optimize reviewers' valuable time and ensure that only papers aligned with publication criteria proceed. Decisions for papers rejected without peer review will be significantly expedited.

The team managing papers post-review and acceptance has been reorganized, now including a Managing Editor and a Publishing Project Editor. The revised process will reduce extensive structural editing after acceptance, placing greater emphasis on author collaboration pre-acceptance. This approach is expected to minimize revisions and facilitate quicker online publication.

A new PDF format has been introduced, and articles are now published continuously rather than being tied to specific issue timings. Monthly compiled issues will commence with the first issue of 2026, replacing the previous schedule of 22 issues per year. The MJA websites are also scheduled for a complete redesign in mid-2026.

Focus on Clinical Guidelines and Best Practices

Clinical guidelines and consensus statements serve as systematic tools to integrate scientific research, clinician experience, and patient perspectives. They are crucial for improving patient care and health outcomes. The MJA publishes summaries of these guidelines to enhance their dissemination and uptake among medical professionals across Australia.

Navigating Challenges in Guideline Development and Dissemination

Several key considerations and challenges are central to the effective development and publication of clinical guidelines:

A recent scoping review by Anneliese Synnot and colleagues, published in the MJA, highlighted a significant area for improvement. The review indicated that extensive lived experience engagement was not reported for the majority of assessed Australian clinical practice guidelines, underscoring a clear need for increased attention to this vital aspect.

For publication consideration, the MJA expects articles presenting new clinical guidance to transparently report methods for generating recommendations alongside key messages. Authors are required to use the AGREE checklist for clinical guidelines and the ACCORD checklist for consensus statements. Disclosure and management of competing interests must adhere to the Guidelines International Network Principles. The strength of recommendations and quality of evidence, often using the GRADE system or an alternative, are also crucial elements.

A significant and ongoing challenge for guideline developers and publishers is ensuring that recommendations keep pace with rapid advances in medical research. Outdated guidelines can potentially contribute to patient harm. Living guidelines have emerged as an innovative approach to address this, with the MJA having published examples in critical areas such as stroke and during the COVID-19 pandemic.

The increase in open access publishing has expanded readership to non-traditional users who may lack extensive clinical or health research experience. This can impact the interpretation and application of clinical guidance. Journals may consider proactively notifying readers when guidance is no longer current, and authors may include anticipated review dates within their publications.

The MJA continues to actively monitor developments in best practices for developing, reporting, and implementing new clinical guidance. The journal welcomes feedback and high-quality submissions relevant to an Australian general medical readership.